Dr. Elizabeth Brem is currently a HS Clinical Associate Professor of Medicine at UC Irvine. At UCI, she sees patient with lymphoma, CLL, and myeloma, attends on the hematologic malignancies service, and is a clinical and translational investigator. Dr. Brem earned her medical degree magna cum laude from SUNY Buffalo as was inducted into Alpha Omega Alpha. She then completed an internal medicine residency and a hematology/oncology fellowship at Beth Israel Deaconess Medical Center in Boston, where she also was a clinical fellow at Harvard Medical School. In Boston, she also did research training at the Dana Farber Cancer Institute in the lab of Dr. Anthony Letai, studying the BCL2 family of proteins and its role as a therapeutic target and source of therapy resistance in lymphomas.
Dr. Brem is an active member of the American Society of Hematology (ASH), a member of the SWOG's Lymphoma Working Group, and chair of the Lymphoma/CLL working group of the the University of California Hematologic Malignancies Consortium. Her goal is to help design and conduct innovative clinical trials for patients with lymphoma.